Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials.

Auteurs : Caparica R, Bruzzone M, Hachem GE, Ceppi M, Lambertini M, Glasberg J, de Azambuja E, Van Laethem JL, Hendlisz A
Jaar : 2020
Journal : Crit Rev Oncol Hematol
Volume : 149
Pagina's : 102940

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Auteurs : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart-Gebhart M, de Azambuja E
Jaar : 2020
Journal : Breast Cancer Res Treat
Volume : 181
Pagina's : 199-209

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Auteurs : Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E
Jaar : 2020
Journal : Clin Breast Cancer
Volume : 20
Pagina's : 262-273.e7

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.

Auteurs : Eiger D, Brandão M, de Azambuja E
Jaar : 2020
Journal : ESMO Open
Volume : 5

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.

Auteurs : Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart-Gebhart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Láng I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E
Jaar : 2020
Journal : Br J Cancer
Volume : 122
Pagina's : 1453-1460

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).

Auteurs : Eiger D, Wagner M, Pondé NF, Nogueira MS, Buisseret L, de Azambuja E
Jaar : 2020
Journal : Acta oncol (Stockholm)
Volume : 59
Pagina's : 723-725

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.

Auteurs : Eiger D, Franzoi MA, Pondé N, Brandão M, de Angelis C, Schmitt Nogueira M, de Hemptinne Q, de Azambuja E
Jaar : 2020
Journal : ESMO Open
Volume : 5

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

Auteurs : de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, Collignon J, Lybaert W, Verheezen J, Rutten A, Vuylsteke P, Goeminne JC, Demey W, Van Beckhoven D, Deblonde J, Rottey S, Geukens T, Punie K
Jaar : 2020
Journal : ESMO Open
Volume : 5

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies.

Auteurs : Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, Curigliano G, de Azambuja E
Jaar : 2020
Journal : Eur J Cancer
Volume : 139
Pagina's : 43-50

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.

Auteurs : Di Cosimo S, Porcu L, Agbor-Tarh D, Cinieri S, Franzoi MA, De Santis MC, Saura C, Huober J, Fumagalli D, Izquierdo M, Piccart-Gebhart M, Daidone MG, de Azambuja E
Jaar : 2020
Journal : Breast Cancer Res
Volume : 22
Pagina's : 115

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.

Auteurs : Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Jaar : 2020
Journal : ESMO Open
Volume : 5

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

Auteurs : Franzoi MA, de Azambuja E
Jaar : 2020
Journal : ESMO Open
Volume : 5

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

Auteurs : Agostinetto E, Caparica R, de Azambuja E
Jaar : 2020
Journal : ESMO Open
Volume : 5

Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy.

Auteurs : Caparica R, Amorim L, Amaral P, Uratani L, Muniz D, Hendlisz A, de Azambuja E, Glasberg J, Takahashi TK, Filho EA, Canellas R, Saragiotto D, Sabbaga J, Mak M
Jaar : 2020
Journal : BMJ Support Palliat Care

De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost?

Auteurs : Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, El Saghir N, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Jaar : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 108
Pagina's : 1040-1046

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.

Auteurs : Brandão M, Maurer C, Ziegelmann PK, Pondé NF, Ferreira A, Martel S, Piccart-Gebhart M, de Azambuja E, Debiasi M, Lambertini M
Jaar : 2020
Journal : ESMO Open
Volume : 5

Are We RESPECTing Older Patients With Breast Cancer?

Auteurs : de Azambuja E, Pondé N, Gelber Rd
Jaar : 2020
Journal : J Clin Oncol
Volume : 38
Pagina's : 3727-3730

Clinical management of first-line advanced triple-negative breast cancer patients

Auteurs : Rediti M, Punie K, de Azambuja E, Naert E, Taylor D, Duhoux FP, Denys H, Awada A, Wildiers H, Ignatiadis M
Jaar : 2020
Journal : Belgian J Medical Oncology
Volume : 14(7)
Pagina's : 333-338

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Auteurs : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Jaar : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pagina's : 86-94

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Auteurs : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart-Gebhart M, Gnant M, Baselga J, de Azambuja E
Jaar : 2019
Journal : Lancet Oncol
Volume : 20
Pagina's : 1226-1238